With immune checkpoint inhibitors (ICIs) becoming the mainstay of treatment for many
cancers, managing their immune-related adverse events (irAEs) has become an important …

Cancer remains a leading cause of mortality on a global scale. Lung cancer, specifically non–
small cell lung cancer (NSCLC), is a prominent contributor to this burden. The management …

Abstract Background & Aims Checkpoint inhibitors (CPI) account for increasing numbers of
drug-induced liver injury (DILI) cases. We aimed to determine the incidence rate and risk …

Real-world healthcare data sharing is instrumental in constructing broader-based and larger
clinical datasets that may improve clinical decision-making research and outcomes …

Lung cancer is the most common cause of cancer-related deaths globally. Although smoking-
related lung cancers continue to account for the majority of diagnoses, smoking rates have …

Immune checkpoint inhibitor therapies act through blockade of inhibitory molecules involved
in the regulation of T cells, thus releasing tumor specific T cells to destroy their tumor targets …

Blockade of immune checkpoints has transformed the therapy of several cancers. However,
immune‐related adverse events (irAEs) have emerged as a major challenge limiting the …

Background Incorporating immune checkpoint blockade into perioperative cancer therapy
has improved clinical outcomes. However, the safety of immune checkpoint blockade needs …

Immune checkpoint inhibitors have significantly transformed the treatment paradigm for
metastatic renal cell carcinoma (RCC), offering prolonged overall survival and achieving …

Immune-related adverse events (irAEs) are toxicities that arise after the administration of
monoclonal antibodies targeting immune checkpoints (immune checkpoint inhibitors [ICIs]) …